47045-NPL-Z-UNDP-1 The Global Fund to Fight AIDS, Tuberculosis and Malaria <narrative>Integrated grant to reduce burden of the three diseases with a focus on the migrant population - Nepal (01-Feb-2025-31-Jul-2027)</narrative> Nepal, Multicomponent, United Nations Development Programme Goals: Accelerate Nepal's HIV response to achieve zero new infections, zero AIDS-related deaths, and eliminate HIV inequalities by 2030, as per NHSP 2021-2026; Nepal has set a goal to decrease incidence rate from 238 in 2020/21 to 181 per 100,000 population by 2025/26; decrease mortality rate from 58 in 2020/21 to 23 per 100,000 by 2025/26; end TB epidemic by 2035; eliminate TB by 2050; and reduce the catastrophic cost to zero; Reduce the indigenous malaria cases to zero by 2026 and sustain thereafter; Sustain zero malaria mortality. Objectives: Increase access to people-centered services across the HIV prevention and care continuum; Optimize health outcomes for people living with HIV and key populations; Strengthen community and health system resilience to reduce barriers to HIV prevention, treatment and care; To build and strengthen political commitment, sustainability and patient-friendly health system to end TB; To ensure the identification of TB, diagnosis, quality treatment and prevention; To ensure proportional and equitable access to quality assured diagnosis and treatment in health facilities as per federal structure and implement effective preventive measures to achieve malaria elimination. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme United Nations Development Programme The Global Fund to Fight AIDS, Tuberculosis and Malaria The Global Fund to Fight AIDS, Tuberculosis and Malaria Communications +41 58 791 1700 website@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland The Global Fund to Fight AIDS, Tuberculosis and Malaria Grant Management Division Manab Basnet Fund Portfolio Manager +41 58 791 1700 manab.basnet@theglobalfund.org https://www.theglobalfund.org The Global Fund to Fight AIDS, Tuberculosis and Malaria, Global Health Campus, Chemin du Pommier 40, 1218 Grand-Saconnex, Geneva, Switzerland Nepal HIV Tuberculosis Multicomponent, RSSH Malaria Ensure healthy lives and promote well-being for all at all ages End the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases, and combat hepatitis, water-borne diseases and other communicable diseases Achieve universal health coverage HIV -> Differentiated HIV Testing Services -> Community-based testing for AGYW and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Community-based testing for KP programs HIV -> Differentiated HIV Testing Services -> Community-based testing outside of KP and AGYW programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for adolescent girls and young women (AGYW) and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Facility-based testing for key population (KP) programs HIV -> Differentiated HIV Testing Services -> Facility-based testing outside of key population (KP) and adolescent girls and young women (AGYW) programs HIV -> Differentiated HIV Testing Services -> Self-testing for AGYW and their male sexual partners programs HIV -> Differentiated HIV Testing Services -> Self-testing for KP programs HIV -> Differentiated HIV Testing Services -> Self-testing outside of KP and AGYW programs HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Early infant diagnosis and follow-up HIV testing for exposed infants HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Integrated testing of pregnant women for HIV, syphilis and hepatitis B HIV -> Elimination of vertical transmission of HIV, syphilis and hepatitis B -> Post-natal infant prophylaxis HIV -> Prevention package for other vulnerable populations (OVP) -> Community empowerment for OVP HIV -> Prevention package for other vulnerable populations (OVP) -> Condom and lubricant programming for OVP HIV -> Prevention package for other vulnerable populations (OVP) -> HIV prevention communication, information and demand creation for OVP HIV -> Prevention package for other vulnerable populations (OVP) -> Removing human rights-related barriers to prevention for OVP HIV -> Prevention package for other vulnerable populations (OVP) -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for OVP HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Community empowerment for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Condom and lubricant programming for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> HIV prevention communication, information and demand creation for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Needle and syringe programs for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Opioid substitution therapy and other medically assisted drug dependence treatment for PWID HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Removing human rights-related barriers to prevention for PUD HIV -> Prevention package for people who use drugs (PUD) and their sexual partners -> Sexual and reproductive health services, including STIs, hepatitis, post-violence care for PUD HIV -> Reducing human rights-related barriers to HIV/TB services -> Community mobilization and advocacy for human rights HIV -> Reducing human rights-related barriers to HIV/TB services -> Eliminating stigma and discrimination in all settings HIV -> Reducing human rights-related barriers to HIV/TB services -> Ensuring nondiscriminatory provision of health care HIV -> Reducing human rights-related barriers to HIV/TB services -> Ensuring rights-based law enforcement practices HIV -> Reducing human rights-related barriers to HIV/TB services -> Improving laws, regulations and policies relating to HIV and HIV/TB HIV -> Reducing human rights-related barriers to HIV/TB services -> Increasing access to justice (HIV/TB) HIV -> Reducing human rights-related barriers to HIV/TB services -> Legal literacy ("Know Your Rights") (HIV/TB) HIV -> Reducing human rights-related barriers to HIV/TB services -> Reducing HIV-related gender discrimination, harmful gender norms and violence against women and girls in all their diversity HIV -> Treatment, care and support -> Diagnosis and management of advanced HIV disease (adults and children) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - adults (15 and above) HIV -> Treatment, care and support -> HIV treatment and differentiated service delivery - children (under 15) HIV -> Treatment, care and support -> Treatment monitoring - Viral load and antiretroviral (ARV) toxicity Malaria -> Case management -> Epidemic preparedness Malaria -> Case management -> Facility-based treatment Malaria -> Case management -> Integrated community case management (iCCM) Malaria -> Case management -> Intensified activities for elimination Malaria -> Case management -> Private sector case management Malaria -> Case management -> Therapeutic efficacy surveillance Malaria -> Vector control -> Entomological monitoring Malaria -> Vector control -> Indoor residual spraying (IRS) Malaria -> Vector control -> Insecticide treated nets (ITNs) - Continuous distribution: ANC Malaria -> Vector control -> Insecticide treated nets (ITNs) - Mass campaign: universal Multicomponent -> Program management -> Grant management RSSH -> RSSH/PP: Human resources for health (HRH) and quality of care -> RSSH/PP: Community health workers: In-service training RSSH -> RSSH/PP: Human resources for health (HRH) and quality of care -> RSSH/PP: Integrated supportive supervision for health workers (excluding CHWs) RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Biosafety and biosecurity, infrastructure and equipment RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Laboratory Information systems RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Laboratory supply chain systems RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Laboratory-based surveillance RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: National laboratory governance and management structures RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Quality management systems and accreditation RSSH -> RSSH/PP: Laboratory systems (including national and peripheral) -> RSSH/PP: Specimen referral and transport system RSSH -> RSSH: Community systems strengthening -> Capacity building and leadership development RSSH -> RSSH: Community systems strengthening -> Community engagement, linkages and coordination RSSH -> RSSH: Community systems strengthening -> Community-led monitoring RSSH -> RSSH: Health products management systems -> Planning and procurement capacity RSSH -> RSSH: Health products management systems -> Storage and distribution capacity, design & operations RSSH -> RSSH: Monitoring and evaluation systems -> Analyses, evaluations, reviews and data use RSSH -> RSSH: Monitoring and evaluation systems -> Routine reporting RSSH -> RSSH: Monitoring and evaluation systems -> Surveillance for HIV, tuberculosis and malaria Tuberculosis -> Collaboration with other providers and sectors -> Private provider engagement in TB/DR-TB care Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB diagnosis/drug susceptibility testing (DST) Tuberculosis -> Drug-resistant (DR)-TB diagnosis, treatment and care -> DR-TB treatment, care and support Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Children and adolescents Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Mobile population (migrants/refugees/IDPs) Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - People in prisons/jails/detention centers Tuberculosis -> Key and vulnerable populations (KVP) - TB/DR-TB -> KVP - Urban poor/slum dwellers Tuberculosis -> Removing human rights and gender related barriers to TB services -> Community mobilization and advocacy, including support to TB survivor-led groups Tuberculosis -> Removing human rights and gender related barriers to TB services -> Eliminating TB-related stigma and discrimination Tuberculosis -> Removing human rights and gender related barriers to TB services -> Reducing TB-related gender discrimination, harmful gender norms and violence Tuberculosis -> TB diagnosis, treatment and care -> TB screening and diagnosis Tuberculosis -> TB diagnosis, treatment and care -> TB treatment, care and support Tuberculosis -> TB/DR-TB Prevention -> Infection prevention and control (IPC) Tuberculosis -> TB/DR-TB Prevention -> Screening/testing for TB infection Tuberculosis -> TB/HIV -> TB/HIV - Collaborative interventions Tuberculosis -> TB/HIV -> TB/HIV - Screening, testing and diagnosis Tuberculosis -> TB/HIV -> TB/HIV - Treatment and care 26771662.81 14749594.22 18079105.00 Global Fund commitment to NPL-Z-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 12688844.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5390261.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2662518.00 Global Fund commitment to NPL-Z-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 2662518.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 13031995.00 Global Fund commitment to NPL-Z-UNDPP01. The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 5099684.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 4142562.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3789749.00 Global Fund disbursement to NPL-Z-UNDPP01 (Multilateral). The Global Fund to Fight AIDS, Tuberculosis and Malaria United Nations Development Programme 3814299.31 Expenditure reported by United Nations Development Programme for NPL-Z-UNDPP01, Feb 2025 to Jul 2025. United Nations Development Programme <narrative>Grant page on the data explorer of the Global Fund.</narrative> An overview of a grant over its lifetime. <narrative>Grant terms and conditions.</narrative> General terms and conditions which apply to Global Fund grants. <narrative>2023 - Funding Request - Window 3 - Malaria - Nepal - English</narrative> Funding Request of funding request FR1427-NPL-M. <narrative>2024 - Funding Request - Window 5 - Tuberculosis - Nepal - English</narrative> Funding Request of funding request FR1426-NPL-T. <narrative>2024 - Funding Request - Window 5 - HIV - Nepal - English</narrative> Funding Request of funding request FR1425-NPL-H. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Number of people in prisons and other closed settings that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. <narrative>Percentage of other vulnerable people that have received an HIV test during the reporting period and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of other vulnerable people that have received an HIV test during the reporting period and know their results</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 688876; Denominator: 844332. Numerator: 724948; Denominator: 1302107.53. Numerator: 62512; Denominator: 1302108. Numerator: 487596; Denominator: 764857. Numerator: 741550; Denominator: 1302107.53. Numerator: 487596; Denominator: 764857. Numerator: 330017; Denominator: 764857. Numerator: 552609; Denominator: 764857. Numerator: 623330; Denominator: 771926. <narrative>Percentage of people newly diagnosed with HIV initiated on ART</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of people newly diagnosed with HIV initiated on ART</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 2416; Denominator: 2570. Numerator: 1012; Denominator: 1065. Numerator: 1028; Denominator: 1072. Numerator: 1012; Denominator: 1065. Numerator: 1853; Denominator: 1950. Numerator: 841; Denominator: 885. Numerator: 160; Denominator: 70. Numerator: 841; Denominator: 885. Numerator: 652; Denominator: 686. <narrative>Percentage of people who inject drugs that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Module: Differentiated HIV Testing Services. <narrative>Percentage of people who inject drugs that have received an HIV test during the reporting period in KP-specific programs and know their results</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 662. Numerator: 662. Numerator: 7004. Numerator: 7004. Numerator: 18245. Numerator: 18245. Numerator: 1170; Denominator: 3347; Percentage: 34.96%. Numerator: 1170; Denominator: 3347; Percentage: 34.96%. Numerator: 24741; Denominator: 30125; Percentage: 82.13%. Numerator: 24741; Denominator: 30125; Percentage: 82.13%. Numerator: 25877; Denominator: 34388; Percentage: 75.25%. Numerator: 28502.3; Denominator: 33532; Percentage: 85%. Numerator: 9696; Denominator: 33532; Percentage: 28.92%. Numerator: 184. Numerator: 1809. Numerator: 7703. Numerator: 470. Numerator: 9226. Numerator: 28502; Denominator: 44759.9; Percentage: 63.68%. Numerator: 58960; Denominator: 89933.5; Percentage: 65.6%. Numerator: 30458; Denominator: 45173.59; Percentage: 67.42%. Numerator: 3124; Denominator: 414; Percentage: 754.59%. Numerator: 290. Numerator: 3163. Numerator: 17577. Numerator: 1012. Numerator: 20018. Numerator: 30458; Denominator: 45173.59; Percentage: 67.42%. Numerator: 32447; Denominator: 45591.11; Percentage: 71.17%. <narrative>Percentage of DST laboratories showing adequate performance on External Quality Assurance</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Percentage of DST laboratories showing adequate performance on External Quality Assurance</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 2; Denominator: 2. Numerator: 3; Denominator: 9. Numerator: 0; Denominator: 9. Numerator: 12; Denominator: 21. Numerator: 12; Denominator: 21. Numerator: 14; Denominator: 14. Numerator: 21; Denominator: 21. <narrative>Percentage of people with RR-TB/MDR-TB who did not start treatment and/or started on treatment for MDR-TB who were lost to follow up during the first six months of treatment</narrative> Module: Drug-resistant (DR)-TB diagnosis, treatment and care. <narrative>Percentage of people with RR-TB/MDR-TB who did not start treatment and/or started on treatment for MDR-TB who were lost to follow up during the first six months of treatment</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative. Numerator: 147; Denominator: 693. Numerator: 68; Denominator: 456. Numerator: 81; Denominator: 269. Numerator: 120; Denominator: 1202. Numerator: 60; Denominator: 601. Numerator: 60; Denominator: 601. Numerator: -54; Denominator: 29. Numerator: 43; Denominator: 860. Numerator: 43; Denominator: 860. <narrative>Number of people with TB (all forms) notified among prisoners; *includes only those with new and relapse TB</narrative> Module: Key and vulnerable populations (KVP) - TB/DR-TB. <narrative>Number of people with TB (all forms) notified among prisoners; *includes only those with new and relapse TB</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. <narrative>Percentage of other vulnerable people reached with HIV prevention programs</narrative> Module: Prevention package for other vulnerable populations (OVP). <narrative>Percentage of other vulnerable people reached with HIV prevention programs</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative - other. Numerator: 36285.06. Numerator: 36285.06. Numerator: 51835.8. Numerator: 51835.8. Numerator: 430237.14. Numerator: 430237.14. Numerator: 850195; Denominator: 844332; Percentage: 100.69%. Numerator: 852880; Denominator: 1302107.53; Percentage: 65.5%. Numerator: 121253; Denominator: 1302108; Percentage: 9.31%. Numerator: 1893. Numerator: 12896. Numerator: 106464. Numerator: 872412; Denominator: 1302107.53; Percentage: 67%. Numerator: 573643; Denominator: 764857; Percentage: 75%. Numerator: 573643; Denominator: 764857; Percentage: 75%. Numerator: 456111; Denominator: 764857; Percentage: 59.63%. Numerator: 5164. Numerator: 36476. Numerator: 414471. Numerator: 650128; Denominator: 764857; Percentage: 85%. Numerator: 733330; Denominator: 771926; Percentage: 95%. <narrative>Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs</narrative> Module: Prevention package for people who use drugs (PUD) and their sexual partners. <narrative>Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Module: Prevention package for people who use drugs (PUD) and their sexual partners. <narrative>Percentage of people who inject drugs reached with HIV prevention programs</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 0. Numerator: 0. Numerator: 2037.07. Numerator: 2037.07. Numerator: 27063.93. Numerator: 27063.93. Numerator: 1372; Denominator: 3347; Percentage: 40.99%. Numerator: 1372; Denominator: 3347; Percentage: 40.99%. Numerator: 27729; Denominator: 30125; Percentage: 92.05%. Numerator: 27729; Denominator: 30125; Percentage: 92.05%. Numerator: 29313; Denominator: 34388; Percentage: 85.24%. Numerator: 31500; Denominator: 33532; Percentage: 93.94%. Numerator: 25274; Denominator: 33532; Percentage: 75.37%. Numerator: 528. Numerator: 5320. Numerator: 19426. Numerator: 1368. Numerator: 23906. Numerator: 31690; Denominator: 44759.9; Percentage: 70.8%. Numerator: 31880; Denominator: 45173.6; Percentage: 70.6%. Numerator: 31880; Denominator: 45173.59; Percentage: 70.57%. Numerator: 27584; Denominator: 45174; Percentage: 61.06%. Numerator: 464. Numerator: 4363. Numerator: 22757. Numerator: 1193. Numerator: 26391. Numerator: 32070; Denominator: 45173.59; Percentage: 70.99%. Numerator: 32447; Denominator: 45591.11; Percentage: 71.17%. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Module: TB diagnosis, treatment and care. <narrative>Percentage of new and relapse TB patients tested using WHO recommended rapid diagnostic tests at the time of diagnosis</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. Numerator: 12045; Denominator: 19746. Numerator: 6504; Denominator: 18284. Numerator: 27864; Denominator: 42868. Numerator: 13932; Denominator: 21434. Numerator: 13932; Denominator: 21434. Numerator: 4076; Denominator: 2752. Numerator: 16382; Denominator: 23402. Numerator: 16382; Denominator: 23402. <narrative>Percentage of notified patients with all forms of TB (i.e., bacteriologically confirmed + clinically diagnosed) contributed by non-national TB program providers- private/non-governmental facilities; *includes only those with new and relapse TB</narrative> Module: TB diagnosis, treatment and care. <narrative>Percentage of notified patients with all forms of TB (i.e., bacteriologically confirmed + clinically diagnosed) contributed by non-national TB program providers- private/non-governmental facilities; *includes only those with new and relapse TB</narrative> Geographic coverage: Subnational, less than 100% national program target. Aggregation: Non cumulative. Numerator: 2725; Denominator: 23061. Numerator: 2820; Denominator: 19746. Numerator: 1475; Denominator: 18284. Numerator: 3405; Denominator: 21434. Numerator: 6810; Denominator: 42868. Numerator: 3405; Denominator: 21434. Numerator: 292; Denominator: 2752. Numerator: 4110; Denominator: 23402. Numerator: 4110; Denominator: 23402. <narrative>Percentage of people living with HIV and currently on antiretroviral therapy who are receiving multi month dispensing of antiretroviral medicine</narrative> Module: Treatment, care and support. <narrative>Percentage of people living with HIV and currently on antiretroviral therapy who are receiving multi month dispensing of antiretroviral medicine</narrative> Geographic coverage: National, 100% of national program target. Aggregation: Non cumulative - other. Numerator: 5513; Denominator: 22421; Percentage: 24.59%. Numerator: 5513; Denominator: 22421; Percentage: 24.59%. Numerator: 534; Denominator: 1381; Percentage: 38.67%. Numerator: 534; Denominator: 1381; Percentage: 38.67%. Numerator: 6024; Denominator: 25728; Percentage: 23.41%. Numerator: 6484; Denominator: 26374; Percentage: 24.58%. Numerator: 6702; Denominator: 27054; Percentage: 24.77%. Numerator: 0. Numerator: 0. Numerator: 7578; Denominator: 27039; Percentage: 28%. Numerator: 6943; Denominator: 26704.24; Percentage: 26%. Numerator: 7578; Denominator: 27039; Percentage: 28.03%. Numerator: 14940; Denominator: 28346; Percentage: 52.71%. Numerator: 14746. Numerator: 194. Numerator: 8212; Denominator: 27374.63; Percentage: 30%. Numerator: 9586; Denominator: 27381; Percentage: 35.01%.